CRSP CRISPR Therapeutics AG

NASDAQ
$38.93

CRISPR Therapeutics AG (CRSP) is expected to report earnings on February 1, 2027, after the market close. The consensus earnings estimate is a loss of $1.27 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -22.5% since its last earnings release on November 2, 2026.

CRISPR Therapeutics AG Missed Consensus Estimates
Monday, November 2, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 1
Monday · 4:00 PM ET
Earnings Whisper
-
vs ($1.27)
Rev est $5.79M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $44.18

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About CRISPR Therapeutics AG

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.